Therefore, using NOACs plus a P2Y12 inhibitor in mild CKD instead of ‘triple therapy’ could be a reasonable alternative, even if these trials did not focus their analysis on the subgroup of CKD patients and despite the lack of a clear indication in the ESC Update. This evidence concerns the gene P2RY12 and chronic kidney disease.